SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 306.69 |
| Enterprise Value ($M) | 290.64 |
| Book Value ($M) | 58.97 |
| Book Value / Share | 0.77 |
| Price / Book | 5.20 |
| NCAV ($M) | 57.40 |
| NCAV / Share | 0.75 |
| Price / NCAV | 5.34 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.74 |
| Return on Assets (ROA) | -0.50 |
| Return on Equity (ROE) | -0.54 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 7.38 |
| Current Ratio | 7.38 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 67.34 |
| Assets | 68.91 |
| Liabilities | 9.94 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Venrock Healthcare Capital Partners II, L.P. | 9.99 | 14.45 | |
| 13G/A | Rubric Capital Management LP | 6.92 | -11.57 | |
| 13D/A | New Enterprise Associates 16, L.P. | 18.70 | 0.00 | |
| 13G/A | Frazier Life Sciences Public Fund, L.P. | 10.20 | 10.77 | |
| 13G/A | Rosalind Advisors, Inc. | 1.03 | -46.10 | |
| 13G/A | Fairmount Funds Management LLC | 0.00 | -100.00 | |
| 13G/A | Viking Global Investors Lp | 9.99 | 7.09 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 88,255 | 368,706 | 23.94 | |
| 128,522 | 623,996 | 20.60 | |
| 74,093 | 556,957 | 13.30 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| TLPH – Talphera, Inc. | TNGX – Tango Therapeutics, Inc. |
| TRDA – Entrada Therapeutics, Inc. | TSBX – Turnstone Biologics Corp. |
| TVTX – Travere Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io